Aclaris Therapeutics, Inc. Stock Issued During Period, Value, Conversion of Convertible Securities
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Aclaris Therapeutics, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2024-09-30 was $21.00K.
- Aclaris Therapeutics, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2024-06-30 was -$10.00K, a 133.33% decline year-over-year.
- Aclaris Therapeutics, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2024-03-31 was -$55.00K.
- Aclaris Therapeutics, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2023-09-30 was -$86.00K.
- Aclaris Therapeutics, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2023 was $8.00K.
- Aclaris Therapeutics, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2022 was -$163.00K, a 110.36% decline from fiscal 2021.
- Aclaris Therapeutics, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2021 was $1.57M.
- Aclaris Therapeutics, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2020 was -$669.00K.
| Period end | Stock Issued During Period, Value, Conversion of Convertible Securities 3 month | Stock Issued During Period, Value, Conversion of Convertible Securities 12 month |
|---|---|---|
| 2024-09-30 | $21.00K 10-Q · filed 2024-11-06 | |
| 2024-06-30 | -$10.00K 10-Q · filed 2024-11-06 | |
| 2024-03-31 | -$55.00K 10-Q · filed 2024-11-06 | |
| 2023-12-31 | $8.00K 10-K · filed 2024-02-27 | |
| 2023-09-30 | -$86.00K 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $30.00K 10-Q · filed 2024-11-06 | |
| 2022-12-31 | -$163.00K 10-K · filed 2024-02-27 | |
| 2022-09-30 | -$11.00K 10-Q · filed 2023-11-06 | |
| 2022-06-30 | $88.00K 10-Q · filed 2023-11-06 | |
| 2022-03-31 | $49.00K 10-Q · filed 2023-11-06 | |
| 2021-12-31 | $1.57M 10-K · filed 2024-02-27 | |
| 2021-09-30 | $29.00K 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $1.04M 10-Q · filed 2022-11-08 | |
| 2021-03-31 | -$2.58M 10-Q · filed 2022-11-08 | |
| 2020-12-31 | -$669.00K 10-K · filed 2023-02-23 | |
| 2015-12-31 | $78.31M 10-K · filed 2018-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |